We are live on ! Find out more
FOLD

Amicus Therapeutics

Delisted

FOLD was delisted on the 24th of April, 2026.

224 hedge funds and large institutions have $2.68B invested in Amicus Therapeutics in 2019 Q4 according to their latest regulatory filings, with 50 funds opening new positions, 86 increasing their positions, 57 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

92% more first-time investments, than exits

New positions opened: 50 | Existing positions closed: 26

65% more call options, than puts

Call options by funds: $9.49M | Put options by funds: $5.74M

51% more repeat investments, than reductions

Existing positions increased: 86 | Existing positions reduced: 57

22% more capital invested

Capital invested by funds: $2.2B → $2.68B (+$482M)

9% more funds holding

Funds holding: 205224 (+19)

0.35% more ownership

Funds ownership: 107.63%107.98% (+0.35%)

14% less funds holding in top 10

Funds holding in top 10: 76 (-1)

Holders
224
Holders Change
+19
Holders Change %
+9.27%
% of All Funds
4.41%
Holding in Top 10
6
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-14.29%
% of All Funds
0.12%
New
50
Increased
86
Reduced
57
Closed
26
Calls
$9.49M
Puts
$5.74M
Net Calls
+$3.74M
Net Calls Change
-$1.35M
Name Holding Trade Value Shares
Change
Change in
Stake
QI
101
QS Investors
New York
$1.3M
Renaissance Technologies
102
Renaissance Technologies
New York
$1.26M -$12.3M -1,340,946 -91%
Royal Bank of Canada
103
Royal Bank of Canada
Ontario, Canada
$1.25M -$5.13K -561 -0.4%
Los Angeles Capital Management
104
Los Angeles Capital Management
California
$1.16M +$897K +97,980 +459%
LCM
105
Laurion Capital Management
New York
$1.15M +$1.08M +118,400 New
MIM
106
MetLife Investment Management
New Jersey
$1.1M
Citigroup
107
Citigroup
New York
$1.07M -$627K -68,491 -38%
Mirae Asset Global Investments
108
Mirae Asset Global Investments
South Korea
$1.04M +$82.4K +9,007 +9%
CSS
109
Cubist Systematic Strategies
Connecticut
$1.03M -$2.14M -233,591 -69%
ACM
110
Asymmetry Capital Management
California
$962K +$904K +98,718 New
EGM
111
Engineers Gate Manager
New York
$956K +$789K +86,197 +718%
IBT
112
International Biotechnology Trust
United Kingdom
$920K +$330K +36,000 +61%
Bank of Montreal
113
Bank of Montreal
Ontario, Canada
$910K +$649K +70,868 +315%
ProShare Advisors
114
ProShare Advisors
Maryland
$875K -$75.8K -8,282 -8%
Susquehanna International Group
115
Susquehanna International Group
Pennsylvania
$856K -$1.9M -208,087 -70%
State Board of Administration of Florida Retirement System
116
State Board of Administration of Florida Retirement System
Florida
$851K
RJA
117
Raymond James & Associates
Florida
$813K +$96.3K +10,522 +14%
QSS
118
Quantitative Systematic Strategies
Florida
$798K +$168K +18,307 +29%
MLICM
119
Metropolitan Life Insurance Company (MetLife)
New York
$775K -$20.1K -2,192 -3%
Jane Street
120
Jane Street
New York
$770K +$724K +79,100 New
AC
121
Athanor Capital
New York
$768K +$252K +27,540 +54%
Principal Financial Group
122
Principal Financial Group
Iowa
$688K +$5.84K +638 +0.9%
VEA
123
Virtus ETF Advisers
New York
$659K +$60.5K +6,608 +11%
PP
124
Paloma Partners
Connecticut
$659K +$620K +67,680 New
NAM
125
Nexpoint Asset Management
Texas
$640K

FOLD Hedge Fund Activity: Q4 2019 in Review

224 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Amicus Therapeutics (FOLD) for Q4 2019, worth a combined $2.68B — up 22% from $2.2B a quarter earlier.

Buyers outnumbered sellers: 50 funds opened new FOLD positions and 26 closed out — a net gain of 24 holders — while 86 added to existing stakes and 57 trimmed.

The largest buyer was JP Morgan Chase, adding an estimated $27.4M. The largest seller was Deutsche Bank, cutting an estimated $36.7M.

  • 224 institutional investors held Amicus Therapeutics (FOLD) as of Q4 2019, up from 205 in Q3 2019.
  • Funds reported $2.68B of Amicus Therapeutics stock for Q4 2019, up 22% quarter-over-quarter.
  • 50 funds opened new Amicus Therapeutics positions in Q4 2019 and 26 closed out, a net change of +24 holders.
  • The largest Amicus Therapeutics buyer in Q4 2019 was JP Morgan Chase, an estimated $27.4M added.
  • The largest Amicus Therapeutics seller in Q4 2019 was Deutsche Bank, an estimated $36.7M sold.

Based on aggregated 13F filings for Q4 2019.